期刊文献+

Absolute Configuration of the Levocloperastine Fendizoate

Absolute Configuration of the Levocloperastine Fendizoate
下载PDF
导出
摘要 Crystal structure of the levocloperastine fendizoate (C80H76Cl2N2O10, C20H25ClNO+· C20H13O4-) has been determined by single-crystal X-ray diffraction. The crystal is of triclinic system, space group P1 with a = 10.1059(18), b = 11.957(2), c = 15.383(3) , α = 104.666(2), β = 90.9700(10), γ = 110.744(2)°, Z = 1, V = 1670.0(5) 3, Dc = 1.289 g/cm3, F(000) = 684, μ(MoKα) = 0.161 mm-1, Mr = 1296.33, the final R = 0.0343 and wR = 0.0676. The cations and anions are linked by the COO…NH hydrogen bonds of 2.709(3) and 2.690(3) and COO…OH hydrogen bonds of 2.632(3) and 2.631(3) . The configuration of the only one chiral carbon atom in this compound is R(rectus). Crystal structure of the levocloperastine fendizoate (C80H76Cl2N2O10, C20H25ClNO+· C20H13O4-) has been determined by single-crystal X-ray diffraction. The crystal is of triclinic system, space group P1 with a = 10.1059(18), b = 11.957(2), c = 15.383(3) , α = 104.666(2), β = 90.9700(10), γ = 110.744(2)°, Z = 1, V = 1670.0(5) 3, Dc = 1.289 g/cm3, F(000) = 684, μ(MoKα) = 0.161 mm-1, Mr = 1296.33, the final R = 0.0343 and wR = 0.0676. The cations and anions are linked by the COO…NH hydrogen bonds of 2.709(3) and 2.690(3) and COO…OH hydrogen bonds of 2.632(3) and 2.631(3) . The configuration of the only one chiral carbon atom in this compound is R(rectus).
出处 《Chinese Journal of Structural Chemistry》 SCIE CAS CSCD 2011年第9期1245-1250,共6页 结构化学(英文)
关键词 absolute configuration levocloperastine fendizoate hydrogen bond absolute configuration levocloperastine fendizoate hydrogen bond
  • 相关文献

参考文献9

  • 1Aliprandi, P.; Cima, L.; Carrara, M. Therapeutic use of levocloperastine as an antitussive agent: an overview of preclinical data and clinical trials in adults and children. Clin. Drug Invest. 2002, 22, 209-220. 被引量:1
  • 2Aliprandi, P.; Castelli, C.; Bernorio, S.; Dell'Abate, E.; Carrara, M. Levocloperastine in the treatment of cough: comparative efficacy versus standard antitussive agents. Drugs Exp. Clin. Res. 2004, 30, 133-141. 被引量:1
  • 3Puricelli, L. Optically active isomer of clopcrastine possessing antitussive activity, a process for its preparation and pharmaceutical compositions which contain it. European Patent, C07D. 0385491.41 1990-05-09. 被引量:1
  • 4http://molcan.en.chenmet.com/suppliers/product/1301168/Levocloperastine.html. 被引量:1
  • 5http://new.kimsonline.co.kr/Data/Contents/NewPackage/DWN_PRU_brochure.pdf/. 被引量:1
  • 6Maribayashi, N.; Fujii, I.; Hirayama, N. Crystal structure of 1-{2-[(p-chloro-a-phenylbenzyl)oxy]ethyl}piperidine fendizoate (cloperastine fendizoate). Anal. Sci. 1999, 15,813-814. 被引量:1
  • 7Puricelli, L. Optically isomers of cloperastine. European patent, C07D. 0894794A1 1999-03-02. 被引量:1
  • 8Sheldrick, G. M. SHELXS 97, Program for the Solution of Crystal Structure. University of Gottingen, Germany 1990. 被引量:1
  • 9Sheldrick, G. M. SHELXL97, Program for Crystal Structure Refinement. University of Gottingen, Germany 1997. 被引量:1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部